Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 78

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 78
---
 cancer treatment places pressure on health systems outside the U.S., including needs for workforce training (oncologists, radiologists, pathologists), equipment, supply chains (for drugs and consumables), and reimbursement mechanisms.

Equity and access concerns: With rising demand, there’s a risk that disparities widen: patients in urban or higher-income regions will access modern treatments, while those in rural or low-income areas might be left behind. Addressing these equity issues is critical.

Public health and prevention: Because treatment demand is growing, complementary efforts in early detection, awareness campaigns, and prevention become increasingly important — earlier detection often means simpler, less costly treatments and better outcomes.

Competitors for Breast Cancer Treatment

There are several potential pharmaceutical companies that we deem as competitors actively developing breast cancer treatment drugs internationally. These companies include:

| ● | Roche                                                                                                                                     
 Holding AG ((ROG.SW)) – Roche has developed Herceptin, which was approved by the FDA in 2023. The first HER2-targeted therapy,            
 for HER2-positive breast cancer. Herceptin was first FDA-approved in September 1998 to treat HER2-positive metastatic breast cancer.      
 It was later approved in 2006 for early-stage HER2-positive breast cancer and in 2010 for HER2-positive metastatic stomach cancer.        
 A new formulation for subcutaneous injection was approved in 2019. Additionally, Roche developed Kadcyla, a HER2-targeted antibody-drug   
 conjugate (ADC) for HER2-positive breast cancer.                                                                                          |
| ● | Pfizer                                                                                                                                    
 Inc. (NYSE: PFE) – Pfizer has developed Ibrance, a CDK4/6 inhibitor, used for hormone receptor (HR)+, HER2- negative advanced/metastatic  
 breast cancer. Ibrance (palbociclib) received its first FDA approval in February 2015 via accelerated approval for postmenopausal         
 women with HR+, HER2- advanced or metastatic breast cancer. It later gained regular approval in combination with letrozole in March       
 2017 and received a second regular approval in February 2016 for use with fulvestrant after disease progression on endocrine therapy.     
 In 2019, the approval was expanded to include men with the same type of breast cancer.                                                    |
| ● | Eli                                                                                                                                       
 Lilly and Company (NYSE: LLY) – LLY is developing Verzenio, another CDK4/6 inhibitor for HR+, HER2-